

## Invitees

### **ISPOR 48th Health Technology Assessment Roundtable [Europe]**

**Sunday, 3 November 2018 – 08:30 – 17:30**

**Bella Center Copenhagen (Room: Hall B, Room 4 M5-10 (ground fl))  
Copenhagen, Denmark**

#### Chair

**Wim Goettsch, PhD, MSc**

Special Advisor, HTA

**Zorginstituut Nederland (ZIN)**

Diemen, Netherlands

#### Co-Chair Elect

**Iga Lipska, MD, PhD**

Plenipotentiary, National Health Fund President for Hospital-based HTA

**HQ National Health Fund**

Warsaw, Poland

#### HTA Council Chair

**Brian O'Rourke, PharmD**

President and Chief Executive Officer

**Canadian Agency for Drugs and Technologies in Health (CADTH)**

Ottawa, ON, Canada

#### HTA Council Advisor

**Finn Børlum Kristensen, MD, PhD**

Professor, Faculty of Health Sciences, **University of Southern Denmark**

External Lecturer, Department of Strategy and Innovation, MSc Innovation in Health Care (IHC), **Copenhagen Business School**

Copenhagen, Denmark

#### Invited Speakers

**Stephanie Earnshaw, PhD**

Senior Vice President, Health Economics

**RTI Health Solutions**

Research Triangle Park, NC, USA

**Rachael Fleurence, PhD**

Executive Director, NEST Coordinating Center

**Medical Device Innovation Consortium (MDIC)**

Arlington, VA, USA

## Invitees

**Panos Kanavos, PhD**

Associate Professor, International Health Policy  
**London School of Economics and Political Science**  
London, England, UK

European Commission

**Flora Giorgio**

Policy Officer, DG SANTE  
**European Commission**  
Brussels, Belgium

World Health Organization

**Sarah Garner, PhD, BPharm**

Program Manager, Medicines and Health Products  
**World Health Organization**  
Copenhagen, Denmark

EUnetHTA

**Niklas Hedberg, MSc**

Chair  
**EUnetHTA JA3 Executive Board**  
Stockholm, Sweden

IHSI

**Marcus Guardian, MA, MBA**

Chief Operations Officer, **EUnetHTA**  
General Manager, **International Horizon Scanning Initiative (IHSI)**  
Diemen, The Netherlands

**Ali Hussain, MSc**

Project Manager, **EUnetHTA**  
Project Manager, **International Horizon Scanning Initiative (IHSI)**  
Diemen, The Netherlands

Austria

**Gottfried Endel, MD**

Head of Department for Evidence Based Economic Health Care  
**Main Association of Austrian Social Security Institutions**  
Vienna, Austria

## Invitees

**Ingrid Rosian-Schikuta, Mag**

Deputy Head, Health Economics Department

**Gesundheit Österreich GmbH (GÖG)**

Vienna, Austria

Belgium

**Francis Arickx**

Head, Directorate Pharmaceutical Policy

**National Institute for Health and Disability Insurance (RIZIV INAMI)**

Brussels, Belgium

**Frank Hulstaert, MD, MSc**

Senior Researcher

**Federal Centre for Health Care Knowledge (KCE)**

Brussels, Belgium

Bosnia and Herzegovina

**Maja Perisic, MD**

Medical Doctor in Health Department (Health Sector)

**Health Insurance Fund**

Banja Luka, Bosnia and Herzegovina

**Siniša Stević, MD, MS**

Director

**Agency for Certification, Accreditation and Health Care Improvement (ASKVA)**

Banja Luka, Bosnia and Herzegovina

Denmark

**Line Brøns Jensen, MSc**

Health Economist

**AMGROS**

Copenhagen, Denmark

**Camilla Nielsen, PhD, MSc**

Research Director, Health Technology Assessment & Health Services Research

**DEFACTUM**

Aarhus, Denmark

Estonia

**Argo Aug**

Chief Specialist, Department of Medicines and Medical Devices

**Haigekassa (Estonian Health Insurance Fund)**

Tallinn, Estonia

## Invitees

### Finland

**Piia Rannanheimo, MSc**

Pharmacoeconomist

**Finnish Medicines Agency**

Kuopio, Finland

**Miia Turpeinen, MD, PhD, MBA**

Head

**National HTA Coordination Unit (FinCCHTA)**

Oulu, Finland

### Germany

**Miriam Luhn, dr rer medic, MS**

Project Lead, EUnetHTA Joint Action 3

**Institute for Quality and Efficiency in Health Care (IQWiG)**

Cologne, Germany

### Hungary

**Fanni Ispán, MSc**

Reimbursement Analyst

**National Health Insurance Fund of Hungary**

Budapest, Hungary

**Gergő Merész, MSc**

Head, Department of Health Technology Assessment

**National Institute of Pharmacy and Nutrition (NIPN)**

Budapest, Hungary

### Ireland

**Roisin Adams, PhD, MSc**

Chief Pharmacist, **Health Service Executive**

Deputy Head, **National Centre for Pharmacoeconomics**

Dublin, Ireland

**Christopher Fawsitt, PhD**

Senior Health Economist, Health Technology Assessment Directorate

**Health Information and Quality Authority (HIQA)**

Dublin, Ireland

## Invitees

### Italy

**Agnese Cangini, MSc**

Health Economist

**Agenzia Italiana del Farmaco (AIFA)**

Rome, Italy

### Latvia

**Antra Fogle**

Head of the Health Technology Assessment Unit

**State Agency of Medicines**

Riga, Latvia

### Lithuania

**Simona Stankevičiutė, MD**

Advisor

**State Medicines Control Agency**

Vilnius, Lithuania

### Malta

**Antonia Formosa**

Director, Pharmaceutical Affairs

**Ministry of Health**

Valletta, Malta

**Sylvana Magrin Sammut, MSc**

Senior Pharmacist, Department Pharmaceutical Affairs

**Ministry of Health**

Valletta, Malta

### Netherlands

**Saskia Knies, PhD, MPhil**

Senior Pharmacoeconomic Assessor

**National Health Care Institute (ZIN)**

Diemen, The Netherlands

### Norway

**Krystyna Hviding, PhD**

Senior Advisor – HTA, HTA Unit

**Norwegian Medicines Agency**

Oslo, Norway

## Invitees

### **Øyvind Melien, MD, PhD, MSc**

Department Director, Reviews and HTA  
**Norwegian Institute of Public Health**  
Oslo, Norway

### Portugal

#### **Dra. Margarida Oliveira**

Pharmacist  
**INFARMED**  
Lisbon, Portugal

### Romania

#### **Felicia Ciulu-Costinescu, PhD**

Head of HTA, Romanian National Drug Agency  
**Ministry of Health**  
Bucharest, Romania

### Russian Federation

#### **George Khachatryan, MD**

Head, Department of Comprehensive Health Technology Assessment, FSBI Center of Healthcare Quality Assessment and Control  
**Ministry of Health of the Russian Federation**  
Moscow, Russia

### Slovakia

#### **Tomas Tesar, PharmD, PhD, MBA**

Member, Reimbursement Committee  
**Union Health Insurance Fund**  
Bratislava, Slovakia

### Sweden

#### **Sophie Werkö, PhD, MSc**

Project Director, **Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)**  
Chair, **The International Network of Agencies for Health Technology Assessment (INAHTA)**  
Stockholm, Sweden

### Switzerland

#### **Goedele van Haasteren, PhD**

Staff Member, HTA Department  
**Swiss Federal Office of Public Health**  
Berne, Switzerland

## Invitees

### Turkey

**Kagan Atikeler, MPharm**

Pharmacist - Advisor to Vice President

**Health Technology Assessment, Turkish Medicines and Medical Devices Agency**

Ankara, Turkey

### Ukraine

**Oresta Piniashko, PhD**

Director, HTA Department, State Expert Centre and Member, Expert Committee

**Ministry of Health of Ukraine**

Kyiv, Ukraine

### United Kingdom

**Meindert Boysen, PharmD, MSc**

Director, Centre for Health Technology Evaluation

**National Institute for Health and Clinical Excellence (NICE)**

Manchester, England, United Kingdom

**Anne Lee**

Chief Pharmacist

**Scottish Medicines Consortium (SMC)**

Glasgow, Scotland, United Kingdom

**Danny Palnoch**

Head of Medicines Analysis, Strategy and Policy

**National Health Service**

London, England, United Kingdom

### ISPOR

**Nancy Berg**, CEO & Executive Director

**Richard Willke, PhD**, Chief Science Officer

**Lucinda Orsini, DPM, MPH**, Associate Chief Science Officer

**Julia Chamova, MBA**, Senior Director, Global Networks

**Nadia Naaman**, Senior Director, Scientific and Health Policy Initiatives

**Ramiro Gilardino, MD, MSc**, Director & Content Strategist

**Kelly Lenahan, MPH**, Manager, Scientific and Health Policy Initiatives